IVVD compared with TVTX: revenue, margins and what each company keeps, and the suppliers and customers both name

IVVDInvivyd, Inc.

Mkt capRevenueRevenue

TVTXTravere Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

IVVDInvivyd, Inc.

TVTXTravere Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

IVVD: latest quarter is a loss; flow not drawable. TVTX: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only IVVD 9

—Undisclosed specialty distributor customerunlistedcustomer

—Adimabunlistedsupplier

—WuXi Biologicsunlistedsupplier

—WuXi Biologics (Hong Kong)unlistedsupplier

5 more · IVVD chain ›

Shared 0

No shared counterparties.

Only TVTX 12

LGNDLigand Pharmaceuticalssupplier

—Catalent Pharma Solutionsunlistedsupplier

—Eversanaunlistedsupplier

—

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

Mission Pharmacal

unlistedsupplier

8 more · TVTX chain ›

Price

rebased to 0%

IVVD, solidTVTX, dashed

IVVDInvivyd, Inc.

0.57▼−2.15%

Mkt cap$171.5MRevenue$14MQ2 FY26Revenue$53MFY25

TVTXTravere Therapeutics, Inc.

49.50▼−1.77%

Regular sessionSep 2 '83

Mkt cap$4.7BRevenue$170MQ2 FY26Revenue$491MFY25

Compare

Regular sessionSep 2 '83

IVVDInvivyd, Inc.

TVTXTravere Therapeutics, Inc.

0.57▼−2.15%

Price

49.50▼−1.77%

$171.5M

Mkt cap

$4.7B

Q2 FY26$14M

Revenue

$170MQ2 FY26

FY25$53M

Revenue

$491MFY25

IVVD0.57▼−2.15%vsTVTX49.50▼−1.77%Regular sessionSep 2 '83